News
10-30-2009, 04:12 AM
Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors[1]. "All tumors detected with the new biomarker were malignant and expressed the targeted VPAC1 receptors located on the plasma membrane of the tumor cells.
More... (http://www.medicalnewstoday.com/articles/169234.php)
More... (http://www.medicalnewstoday.com/articles/169234.php)